Medistim strengthens its Commercial Operations

31 Jan 2025 10:03 CET

(Oslo, 31 January 2025) Medistim ASA (OSE: MEDI) is a niche market leader within
ultrasound technology with headquarters in Oslo, Norway. Medistim develops and
commercializes medical equipment for use within cardiac, vascular and transplant
surgery.

Today, the company announces the strengthening of its commercial operations with
the appointment of Mr. Mike Karim as Chief Commercial Officer (CCO), reporting
to the President and CEO. Mr. Karim brings deep industry expertise, strategic
insight, and a proven track record from leadership roles at esteemed companies
such as Boston Scientific, Lombard Medical, HeartWare, and Oxford Endovascular,
with a focus on the cardiac and vascular fields. With a strong foundation in
sales, he has led Sales, Marketing, and General Management functions,
successfully driving growth in international markets.

Furthermore, leadership of Medistim’s AMERICAS sales region—including its
largest current market and greatest growth opportunity, the USA—has been
entrusted to Mr. Tony Winter. Mr. Winter brings extensive commercial leadership
experience across the cardiac, vascular, interventional, and surgical sectors.
With more than a decade at Medtronic, contributions to Synovis Life
Technologies, and most recently, leadership of the U.S. sales organization at
ACIST Medical Systems, he is well-positioned to drive Medistim’s continued
expansion in the region.

“Medistim stands at a pivotal moment as we enter 2025, poised for significant
growth driven by the launch of the INTUI software platform, which is advancing
innovation in the Cardiac segment, and a focused strategy in the Vascular
segment, supported by the PATENT study and our commitment to advancing
Peripheral Bypass,” says Medistim President and CEO Kari E. Krogstad. “This is
the perfect time to strengthen our commercial efforts. With these strategic
additions to our team, enhanced commercial initiatives, and a focus on fostering
collaboration and sharing best practices across all regions, I am confident we
will accelerate growth throughout this year and beyond.”

In his CCO role, Mr. Karim will lead and support the efforts of Tony Winter
(AMERICAS), Stephanie Stenhagen (EMEA), and Roger Morberg (APAC) as they
continue driving Medistim’s growth and success.

About Medistim:
Medistim was established in 1984 and has a track record of profitable growth
over the past 20 years. The company is a pioneer within its segment and
continues to invest in new product development. Medistim has wholly owned
subsidiaries with sales organizations in the USA, Canada, China, Germany, UK,
Spain, Denmark, Sweden and Norway, in addition to more than 60 distributors in
Europe, Asia, Middle East, Africa, and South America. For more information,
visit the Medistim home page: www.medistim.com

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA
Tel: + 47 918 38 110
Email: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA
Tel: + 47 906 59 940
Email: thomas.jakobsen@medistim.com

More information:
Access the news on Oslo Bors NewsWeb site